MP33-06 INTRALESIONAL COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ACHIEVES GREATER CURVATURE IMPROVEMENTS COMPARED TO INTERFERON FOR PEYRONIE'S DISEASE

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Peyronie's Disease (MP33)1 Apr 2020MP33-06 INTRALESIONAL COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ACHIEVES GREATER CURVATURE IMPROVEMENTS COMPARED TO INTERFERON FOR PEYRONIE'S DISEASE Manaf Alom*, Yifan Meng, Hoang MT Nguyen, Kiran Sharma, Matthew Ziegelmann, Wayne Hellstrom, and Landon Trost Manaf Alom*Manaf Alom* More articles by this author , Yifan MengYifan Meng More articles by this author , Hoang MT NguyenHoang MT Nguyen More articles by this author , Kiran SharmaKiran Sharma More articles by this author , Matthew ZiegelmannMatthew Ziegelmann More articles by this author , Wayne HellstromWayne Hellstrom More articles by this author , and Landon TrostLandon Trost More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000877.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Collagenase Clostridium Histolyticum (CCH) is the first medical therapy approved by the FDA to treat Peyronie’s Disease (PD). Although it has demonstrated safety and efficacy, it remains significantly more expensive than alternative injection therapies. Additionally, some authors have questioned the efficacy of CCH compared to the historical injection treatments such as interferon (IFN). As there are no studies directly comparing the efficacy of CCH to other injections, we sought to perform an overlay analysis of men undergoing CCH or interferon to evaluate for differences in efficacy. METHODS: A comparative analysis was performed of two databases from two separate institutions of men undergoing intralesional injections for PD. The CCH data were collected via a prospective registry, while the IFN data were retrospectively obtained from chart reviews. Demographic variables included age, body mass index, PD duration, and prior PD therapies. Objective penile curvature and length assessments were performed following intracavernosal injection of erectogenic medication prior to and following completion of therapy. Statistical analyses were then performed to evaluate for differences between IFN and CCH. RESULTS: A total of 346 patients underwent CCH (n=242) or IFN (n=104) injections for PD. CCH men were older than the IFN cohort (56.9 vs 54.7 years, p=0.03), had a shorter duration of PD (2.3 vs 2.7, p<0.0001), and had a larger pre-treatment curvature (62.3 vs 48.3, p<0.0001). Overall, results demonstrated consistently larger improvements with CCH, with absolute improvements of 19° (CCH) versus 9.4° (IFN, p<0.001). Similarly, the percent improvement was larger for CCH (29% vs 20.3%, p<0.001). CCH men were also more likely to achieve a ≥20% improvement in curvature (71.1% vs 47.1%, p<0.0001), with CCH being 2.8x more likely to achieve a ≥20% improvement (p<0.0001) and 2.4x more likely to experience ≥30% improvement (p<0.001). CONCLUSIONS: Using a comparative analysis from two, high-volume PD institutions, CCH was more likely to improve penile curvature and achieve greater results compared to IFN. These data would suggest that CCH should be considered preferentially over IFN as an injection therapy for PD. Source of Funding: none © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e496-e496 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Manaf Alom* More articles by this author Yifan Meng More articles by this author Hoang MT Nguyen More articles by this author Kiran Sharma More articles by this author Matthew Ziegelmann More articles by this author Wayne Hellstrom More articles by this author Landon Trost More articles by this author Expand All Advertisement PDF downloadLoading ...